Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2002-09-05

Original market date: See footnote 1

2002-09-05

Product name:

TRILEPTAL ORAL SUSPENSION

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02244673

Product Monograph/Veterinary Labelling:

Date: 2021-06-04 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

NOVARTIS PHARMACEUTICALS CANADA INC
385 Bouchard Blvd
Dorval
Quebec
Canada H9S 1A9

Class:

Human

Dosage form(s):

Suspension

Route(s) of administration:

Oral

Number of active ingredient(s):

1

Schedule(s):

Prescription

 

Anatomical Therapeutic Chemical (ATC): See footnote 4

N03AF02 OXCARBAZEPINE

Active ingredient group (AIG) number:See footnote5

0140461004

List of active ingredient(s)
Active ingredient(s) Strength
OXCARBAZEPINE 60 MG / ML
Version 4.0.0
Date modified: